{"id":"rabeprazole-amoxicillin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Diarrhea"},{"rate":"3-10","effect":"Nausea"},{"rate":"2-8","effect":"Abdominal pain"},{"rate":"2-5","effect":"Headache"},{"rate":"1-3","effect":"Rash (amoxicillin-related)"},{"rate":"1-2","effect":"Taste disturbance"}]},"_chembl":{"chemblId":"CHEMBL1219","moleculeType":"Small molecule","molecularWeight":"359.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rabeprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an environment where amoxicillin (a beta-lactam antibiotic) can effectively penetrate and kill H. pylori bacteria by disrupting their cell wall synthesis. This combination therapy is a standard triple or dual therapy regimen for H. pylori eradication, typically used with a third agent such as clarithromycin or metronidazole.","oneSentence":"Rabeprazole and amoxicillin work together to eradicate Helicobacter pylori by suppressing gastric acid and inhibiting bacterial cell wall synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:36.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT07408271","phase":"","title":"The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-24","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Eradication Antibiotic","enrollment":83},{"nctId":"NCT07358130","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2025-10-21","conditions":"Helicobacter Pylori Infection","enrollment":552},{"nctId":"NCT06349486","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2023-11-28","conditions":"Helicobacter Pylori Eradication","enrollment":390},{"nctId":"NCT07211880","phase":"NA","title":"Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study","status":"COMPLETED","sponsor":"Zero Helicobacter IGAN Network","startDate":"2019-12-05","conditions":"H.Pylori, Gastric Cancer, H Pylori Eradication","enrollment":1043},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":"H.Pylori Infection","enrollment":700},{"nctId":"NCT07122024","phase":"PHASE4","title":"Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-02-19","conditions":"Helicobacter Pylori","enrollment":414},{"nctId":"NCT03897244","phase":"PHASE4","title":"Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-05-30","conditions":"Helicobacter Pylori Infection","enrollment":603},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT03320538","phase":"NA","title":"Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases","status":"COMPLETED","sponsor":"Jiangxi University of Traditional Chinese Medicine","startDate":"2017-07-10","conditions":"Peptic Ulcer Disease","enrollment":360},{"nctId":"NCT06076694","phase":"PHASE2","title":"Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2022-06-26","conditions":"Helicobacter Pylori Infection","enrollment":80},{"nctId":"NCT06076681","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2021-09-27","conditions":"Helicobacter Pylori Infection","enrollment":40},{"nctId":"NCT02407119","phase":"PHASE3","title":"Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2003-06","conditions":"Helicobacter Pylori Infection, Early Gastric Cancer, Endoscopic Resection","enrollment":470},{"nctId":"NCT02547025","phase":"NA","title":"Personalized Treatment for Refractory H Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2012-08-01","conditions":"Helicobacter Pylori Infection","enrollment":126},{"nctId":"NCT03779074","phase":"PHASE3","title":"Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-09-03","conditions":"Helicobacter Pylori Infection","enrollment":918},{"nctId":"NCT06037122","phase":"","title":"Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09","conditions":"Helicobacter Pylori Infection","enrollment":558},{"nctId":"NCT06004401","phase":"NA","title":"The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-08-20","conditions":"The Eradication Rate of Helicobacter Pylori","enrollment":400},{"nctId":"NCT05870397","phase":"NA","title":"Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective Randomized Trial","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-04-21","conditions":"Helicobacter Pylori Eradication","enrollment":900},{"nctId":"NCT05718609","phase":"PHASE4","title":"Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-01","conditions":"Helicobacter Pylori Infection","enrollment":855},{"nctId":"NCT04923113","phase":"NA","title":"Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-06-28","conditions":"Helicobacter Pylori Infection","enrollment":281},{"nctId":"NCT05419674","phase":"PHASE4","title":"Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-08-01","conditions":"Helicobacter Pylori Infection","enrollment":393},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT05014334","phase":"PHASE4","title":"Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2021-12-01","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":300},{"nctId":"NCT04697186","phase":"PHASE4","title":"Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2021-01-07","conditions":"Dyspepsia, Chronic Gastritis, Gastric Cancer","enrollment":524},{"nctId":"NCT05364619","phase":"NA","title":"Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2022-08-05","conditions":"Helicobacter Pylori Infection","enrollment":160},{"nctId":"NCT05152004","phase":"NA","title":"Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2018-09-01","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT05226819","phase":"NA","title":"Influencing Factors of Helicobacter Pylori Infection and Eradication Failure","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2022-02-06","conditions":"Helicobacter Pylori Infection","enrollment":300},{"nctId":"NCT05191888","phase":"PHASE4","title":"14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2021-08-06","conditions":"Helicobacter Pylori Eradication","enrollment":906},{"nctId":"NCT05061732","phase":"PHASE4","title":"Helicobacter Pylori Eradication and Follow-up","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-30","conditions":"Helicobacter Pylori Infection","enrollment":4447},{"nctId":"NCT05014685","phase":"PHASE4","title":"PPI-amoxicillin for H. Pylori Treatment","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08-20","conditions":"Helicobacter Pylori Infection","enrollment":732},{"nctId":"NCT04209933","phase":"PHASE4","title":"Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-05-25","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":240},{"nctId":"NCT04667299","phase":"PHASE4","title":"Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-12-20","conditions":"Helicobacter Pylori Infection","enrollment":270},{"nctId":"NCT03908619","phase":"PHASE4","title":"A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis","status":"UNKNOWN","sponsor":"Changi General Hospital","startDate":"2019-04-16","conditions":"Helicobacter Pylori Infection","enrollment":252},{"nctId":"NCT03658746","phase":"PHASE4","title":"Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shandong University","startDate":"2019-01-01","conditions":"Helicobacter Pylori Infection","enrollment":420},{"nctId":"NCT03565484","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-01-01","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT02490839","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT04132479","phase":"PHASE4","title":"The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2018-01-01","conditions":"Helicobacter Pylori Infection","enrollment":313},{"nctId":"NCT01967329","phase":"PHASE4","title":"CANHelp Working Group Treatment Trials","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2008-11","conditions":"Helicobacter Pylori Infection","enrollment":338},{"nctId":"NCT04061447","phase":"NA","title":"Tailored Juice-guided Eradication Therapy","status":"COMPLETED","sponsor":"Kaohsiung Medical University","startDate":"2016-02-05","conditions":"Helicobacter Pylori Infection","enrollment":182},{"nctId":"NCT03997279","phase":"PHASE4","title":"Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii","status":"UNKNOWN","sponsor":"Clinical Centre of Serbia","startDate":"2019-06","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT02483715","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":589},{"nctId":"NCT03616405","phase":"PHASE4","title":"Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-04-01","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT03521726","phase":"PHASE4","title":"Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2018-05-11","conditions":"Helicobacter Pylori Infection","enrollment":20},{"nctId":"NCT03802318","phase":"NA","title":"Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-01-02","conditions":"Helicobacter Pylori Infection, Helicobacter Gastritis, Helicobacter-Associated Pyloric Ulcer","enrollment":530},{"nctId":"NCT02776371","phase":"PHASE4","title":"Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong University","startDate":"2016-09","conditions":"Helicobacter Pylori Eradication Rate","enrollment":301},{"nctId":"NCT03658733","phase":"PHASE4","title":"A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-12-15","conditions":"Helicobacter Pylori Infection","enrollment":120},{"nctId":"NCT03361267","phase":"NA","title":"Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection","status":"UNKNOWN","sponsor":"Inha University Hospital","startDate":"2017-12-30","conditions":"Helicobacter Pylori Infection, Compliance, Patient, Drug Resistance","enrollment":300},{"nctId":"NCT03134378","phase":"PHASE4","title":"10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2016-10-03","conditions":"Helicobacter Pylori Infection","enrollment":73},{"nctId":"NCT03108287","phase":"PHASE4","title":"Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2013-04-01","conditions":"Helicobacter Pylori Infection","enrollment":162},{"nctId":"NCT01264822","phase":"","title":"Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-01-13","conditions":"Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive","enrollment":108},{"nctId":"NCT02934152","phase":"PHASE4","title":"Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2016-10","conditions":"Gastroesophageal Reflux Disease","enrollment":400},{"nctId":"NCT02635191","phase":"PHASE4","title":"Tailored Therapy for Helicobacter Pylori in Children","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2014-03","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT02541786","phase":"PHASE4","title":"Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University","startDate":"2015-01","conditions":"Helicobacter Pylori Infection","enrollment":177},{"nctId":"NCT02368470","phase":"PHASE3","title":"Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-02","conditions":"Helicobacter Pylori Infection","enrollment":252},{"nctId":"NCT01922765","phase":"PHASE4","title":"Concomitant Therapy of H. Pylori","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2013-08","conditions":"Gastritis, Gastric Ulcer, and Duodenal Ulcer","enrollment":540},{"nctId":"NCT01219764","phase":"PHASE4","title":"A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2010-10","conditions":"Helicobacter Infections","enrollment":200},{"nctId":"NCT01163435","phase":"PHASE4","title":"Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2010-08","conditions":"Helicobacter Infection","enrollment":618},{"nctId":"NCT01453036","phase":"PHASE4","title":"Clarithromycin Resistant Tailored Therapy","status":"COMPLETED","sponsor":"Jin Il Kim","startDate":"2011-08","conditions":"Peptic Ulcer, Helicobacter Pylori Infection","enrollment":924},{"nctId":"NCT01922505","phase":"","title":"Eradication Rates of Helicobacter Pylori and Its Affecting Factors","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2003-01","conditions":"Helicobacter Infections","enrollment":2500},{"nctId":"NCT01265069","phase":"PHASE4","title":"Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-11","conditions":"Helicobacter Pylori Infection","enrollment":204},{"nctId":"NCT01805934","phase":"PHASE2","title":"Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-05","conditions":"Rescue Therapy for Helicobacter Pylori","enrollment":114},{"nctId":"NCT01575899","phase":"PHASE4","title":"Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori","status":"TERMINATED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2007-12","conditions":"Helicobacter Pylori Infection","enrollment":208},{"nctId":"NCT01573975","phase":"PHASE4","title":"Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2009-01","conditions":"Helicobacter Pylori Infection","enrollment":345},{"nctId":"NCT01572597","phase":"PHASE4","title":"Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2011-06","conditions":"Bacterial Infection Due to Helicobacter Pylori (H. Pylori)","enrollment":120},{"nctId":"NCT01566643","phase":"PHASE4","title":"Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2011-01","conditions":"Helicobacter Pylori Infection","enrollment":231},{"nctId":"NCT01513785","phase":"PHASE2","title":"New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-04","conditions":"Functional Dyspepsia","enrollment":40},{"nctId":"NCT01002443","phase":"PHASE2","title":"Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2003-07","conditions":"Gastric Cancer","enrollment":190},{"nctId":"NCT00197418","phase":"PHASE2, PHASE3","title":"Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection","status":"UNKNOWN","sponsor":"Hamamatsu University","startDate":"2003-08","conditions":"Helicobacter Infections, Gastritis, Gastric Ulcer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pariet, Supercillin"],"phase":"marketed","status":"active","brandName":"Rabeprazole, Amoxicillin","genericName":"Rabeprazole, Amoxicillin","companyName":"Mackay Memorial Hospital","companyId":"mackay-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rabeprazole is a small molecule medication used to treat Helicobacter Pylori Infection, Helicobacter Gastritis, and Helicobacter-Associated Pyloric Ulcer, often in combination with other medications such as amoxicillin. Amoxicillin is an antibiotic that is commonly used in combination with rabeprazole to treat these conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}